In the case of Pfizer Inc. et al. v. Government of India et al., 1977, the Supreme Court ruled that foreign nations are allowed to bring legal action against American companies in U.S courts for violations of antitrust laws. The Indian government and other foreign governments accused Pfizer and several other pharmaceutical companies of price-fixing tetracycline, an antibiotic drug commonly used worldwide at that time. The defendants argued that foreign plaintiffs should not be permitted to seek treble damages under Section 4 of the Clayton Act because they were not directly purchasing from them but through intermediaries instead; thus, they claimed there was no direct injury caused by their actions. However, the court rejected this argument stating that a violation could occur even if purchases were made indirectly or outside U.S territory as long as it resulted in domestic effects violating U.S antitrust laws - such as artificially inflated prices due to alleged collusion among manufacturers which affected consumers globally including those in India who purchased via importers or distributors.

In the dissenting opinion for Pfizer Inc. et al. v. Government of India et al., Justice Rehnquist disagreed with the majority's interpretation of antitrust laws, arguing that they were not intended to apply to foreign nations in this manner. He contended that Congress did not intend for these laws to be used by a foreign nation as a purchaser of goods, especially when there was no direct harm done within U.S borders or its commerce system. Furthermore, he argued that extending such rights could potentially disrupt international relations and diplomacy due to conflicts arising from differing national policies on competition and trade practices.